Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients.
biological predictors
hepatocellular carcinoma
immune activation
immune senescence
post-transplant malignancy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
03
2022
accepted:
16
05
2022
entrez:
30
6
2022
pubmed:
1
7
2022
medline:
1
7
2022
Statut:
epublish
Résumé
Liver transplanted (LT) patients for hepatocellular carcinoma (LT-HCC) or for other causes (LT-no-HCC) may develop post-transplantation malignancies. Although immune activation and senescence are frequently implicated in cancer development, no data is available on their possible role as biomarkers predictive of tumor onset in this setting. A total of 116 patients were investigated: the 45 LT-HCC patients were older than the 71 LT-non-HCC (p=0.011), but comparable for sex, HCV, HBV infection and immunosuppressive treatment. At baseline, the numbers of activated and senescent-like circulating cells were significantly higher in LT-HCC patients than in LT-no-HCC ones. After a median follow-up of 26.8 months, 6 post-transplant malignancies (PTM) occurred: 4 in LT-HCC (8.9%) and 2 in LT-no-HCC (2.8%) patients. Overall, subjects with high percentages of activated and exhausted T and B cells at baseline were at higher risk of PTM. Notably, within the LT-HCC group, a higher percentage of senescence-like T cells was also associated with cancer development. Moreover, patients with PTM had higher telomere erosion and higher levels of circulating PAMPs (16S rDNA) and DAMPs (mtDNA) when compared with matched patients without PTM. Overall, these findings suggest that immune activation and exhaustion may be useful to predict the risk of PTM occurrence, regardless of the cause of transplantation. In LT-HCC, T-cell senescence represents an additional risk factor for tumor onset.
Identifiants
pubmed: 35769714
doi: 10.3389/fonc.2022.899170
pmc: PMC9235349
doi:
Types de publication
Journal Article
Langues
eng
Pagination
899170Informations de copyright
Copyright © 2022 Petrara, Shalaby, Ruffoni, Taborelli, Carmona, Giunco, Del Bianco, Piselli, Serraino, Cillo, Dolcetti, Burra and De Rossi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Oncol. 2021 Aug 23;11:713637
pubmed: 34497765
Cells. 2021 Nov 26;10(12):
pubmed: 34943822
EBioMedicine. 2021 Jun;68:103409
pubmed: 34049248
Nature. 2012 Jun 13;486(7402):215-21
pubmed: 22699610
Cancer Discov. 2017 May;7(5):522-538
pubmed: 28202625
Cancers (Basel). 2020 Oct 25;12(11):
pubmed: 33113831
Cancer Lett. 2020 Jan 28;469:323-331
pubmed: 31693921
World J Gastroenterol. 2012 Aug 21;18(31):4071-81
pubmed: 22919237
Cancer Lett. 2015 Dec 1;369(1):37-44
pubmed: 26279520
Front Immunol. 2021 Nov 22;12:768098
pubmed: 34880864
Aging Dis. 2017 Oct 1;8(5):628-642
pubmed: 28966806
Cell Mol Immunol. 2020 Jan;17(1):27-35
pubmed: 31853000
Cancers (Basel). 2021 Sep 29;13(19):
pubmed: 34638361
Exp Gerontol. 2013 Dec;48(12):1436-42
pubmed: 24120567
Transpl Int. 2021 Apr;34(4):743-753
pubmed: 33492715
Liver Cancer. 2013 Aug;2(3-4):367-83
pubmed: 24400224
J Clin Invest. 2017 Jun 30;127(7):2464-2472
pubmed: 28530643
Liver Transpl. 2011 Mar;17(3):299-305
pubmed: 21384512
Nature. 2017 Oct 5;550(7674):61-66
pubmed: 28953883
J Cancer Res Clin Oncol. 2019 Dec;145(12):3125-3135
pubmed: 31587105
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604
pubmed: 31439937
Clin Gastroenterol Hepatol. 2017 May;15(5):767-775.e3
pubmed: 28013117
Int J Cancer. 2018 Oct 1;143(7):1588-1594
pubmed: 29693248
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
PLoS One. 2017 Sep 19;12(9):e0185128
pubmed: 28926641
Aging (Albany NY). 2019 Jun 13;11(11):3864-3875
pubmed: 31195370
Nat Chem Biol. 2007 Oct;3(10):640-9
pubmed: 17876321
Liver Transpl. 2018 Oct;24(10):1425-1436
pubmed: 30021061
Clin Cancer Res. 2021 Jan 15;27(2):492-503
pubmed: 32887723
JAMA Oncol. 2016 Apr;2(4):463-9
pubmed: 26746479
NPJ Precis Oncol. 2018 Feb 23;2(1):6
pubmed: 29872724
Front Immunol. 2021 Feb 23;12:611910
pubmed: 33708206
AIDS. 2016 Jun 1;30(9):1363-73
pubmed: 26990630
Nature. 2013 Jul 4;499(7456):97-101
pubmed: 23803760
Transplant Rev (Orlando). 2018 Oct;32(4):218-224
pubmed: 30017342
J Infect Dis. 2014 Aug 1;210(3):392-9
pubmed: 24550442
Int J Cancer. 2019 Jan 15;144(2):232-239
pubmed: 30091809
Front Oncol. 2021 Aug 19;11:729207
pubmed: 34490122